News and Trends 12 Nov 2025 New cancer cell discovery sheds light on childhood blood cancer …consultant paediatric oncologist at Addenbrooke’s Hospital, told Labiotech. That’s why the discovery of these cancerous cells, and more importantly, the switch responsible for their development can help choose the right treatment for patients. “Our findings indicate that there are… November 12, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 New biomarker for early prediction of response to CAR-T cell therapy …for the lymphatic cancer cells, expanded and then returned to the patient. The T cells are turned into killer cells due to the expression of the chimeric T cell receptors… January 9, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 6 May 2025 The future of diabetes treatment: Is a cure possible? …the disease. In 2022, the FDA approved teplizumab (Tzield), making it the first treatment specifically designed to delay the onset of clinical type 1 diabetes. The drug is an anti-CD3… May 6, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 2 Jan 2018 The Labiotech Dictionary of Important Biotech Terms …at Labiotech, we believe that it is important for everyone to follow the changes in the field that could help to save or improve their lives. For that reason, we… January 2, 2018 - 14 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 May 2023 5 cell therapy companies you should know about …use of patients’ own T cells to target and destroy cancer cells. To do this, the company has a proprietary T-cell receptor (TCR) platform that enables it to identify cancer… May 10, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Swiss scientists reduce resistance of dormant melanoma cells Small-molecule targeted therapies revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite an initial response that can be seen… September 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 29 Nov 2022 LAG-3: The next big checkpoint inhibitor target …and small molecules blocking the emerging drug target in addition to antibodies to treat autoimmune diseases. In an interview with Voigt and Triebel, we discussed the progress of the checkpoint… November 29, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 1 Dec 2025 Stem cell therapy’s avant-garde: Eight companies leading the way …Because the cells are autologous, the therapy avoids immune rejection and removes the need for long-term immunosuppression. In April 2024, Aspen dosed the first patient in its phase 1/2a trial, the first… December 1, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Mar 2023 10 immunotherapy companies making waves in 2023 …research, specifically CAR-T cell therapy. One in particular, is a therapy based on CAR-T cell technology, where the T cells are engineered to attack the autoimmune B cells; a therapy… March 15, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 15 Oct 2019 Four New Technologies That Will Change Cancer Treatment …the patient and genetically engineering them to target a specific cancer antigen. “CAR-T is changing the treatment paradigm for cancer by creating targeted treatments that are specific to cancer cells,”… October 15, 2019 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 11 Dec 2024 Targeting sugar molecules: Can glycobiology lead to a new era for cancer immunotherapy? …receptors on immune cells that normally distinguish “self” from “non-self” cells (the body’s own cells are recognized as “self” cells, while cells that do not originate in the body are… December 11, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2023 The promise of immunotherapy for autoimmune diseases …drug, 1104. The candidate binds to monocytes – which mature into dendritic cells – and modifies the regulatory signal that causes them to activate regulatory dendritic cells, regulatory T cells… June 27, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email